



Strategize your chronic rhinosinusitis postoperative care plan

Effective postoperative care is critical to maintaining sinus surgery outcomes in patients with chronic rhinosinusitis (CRS).^{1,2} Intranasal steroid (INS) sprays are commonly prescribed after sinus surgery.³ Suboptimal delivery of low volume topical corticosteroids limit their expected efficacy.⁴ Patients with CRS may benefit from postoperative care with minimized reliance on patient compliance, in order to achieve improved sinus surgery outcomes.



PATIENT COMPLIANCE

After surgery, less than **35% of patients** use INS sprays as prescribed⁵



SINUS PENETRATION

About **60% of the active dose** in a metered dose INS spray is removed by mucociliary clearance within 15 minutes⁶

Overall, the underlying disease is hard to predict and postoperative inflammation related to surgery can hinder the benefits of surgery. So, consider a proven therapy that maintains patency and delivers drug to the mucosa following sinus surgery. **The PROPEL family of implants are inserted by a physician, minimizing reliance on patient compliance.**

PROPEL can improve your sinus surgery outcomes ...





ARMED WITH PROPEL

Add **PROPEL** to your surgical action plan

To minimize reliance on patient compliance


PROPEL implants feature an innovative **2-in-1 mechanism** that opens the sinuses while gradually releasing 370 µg of mometasone furoate.⁷⁻⁹ Mometasone furoate is present in mucosal tissue for **60 days**.^{10*}

PROPEL IMPLANTS CAN REDUCE THE NEED FOR POSTOPERATIVE INTERVENTIONS, WHICH INCLUDE THE NEED FOR ORAL STEROIDS AND SURGICAL INTERVENTIONS^{7-9†}



+PROPEL

For ethmoid sinus⁷



+PROPEL Mini

For ethmoid sinus and frontal sinus recess⁸



+PROPEL Contour

For sinus ostia: frontal and maxillary⁹

*Pre-clinical animal data. †Postoperative interventions was a composite endpoint that included surgical intervention required to separate an adhesion and/or oral steroid intervention to resolve recurrent sinus inflammation, edema, and/or polyp recurrence.

In more than **350K patients since 2011**, the trusted performance of Intersect ENT's PROPEL products have provided patients with **proven improvements in sinus surgery outcomes**.

YOUR PATIENTS + PROPEL = IMPROVED OUTCOMES

Explore the **PROVEN** benefits of the PROPEL family of implants at PROPELOpens.com.



The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

References: **1.** Sedaghat AR. *Am Fam Physician*. 2017;96(8):500-506. **2.** Vennik J, et al. *BMJ Open*. 2018;8(12):e022643. **3.** Portela RA, et al. *Int Forum Allergy Rhinol*. 2012;2(1):27-33. **4.** Shen J, et al. *Expert Rev Clin Pharmacol*. 2018;11(12):1163-1170. **5.** Hankin CS, et al. *Allergy Asthma Proc*. 2012;33(3):258-264. **6.** Shah SA, et al. *Allergy Asthma Proc*. 2015;36(1):48-57. **7.** PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013. **8.** PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. **9.** PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. **10.** Li PM, et al. *Am J Rhinol Allergy*. 2009;23(6):591-596.

Intersect ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries.

©2020 Intersect ENT, Inc. All rights reserved. MPM-11744 Rev 1.0